Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CCXI ChemoCentryx	$51.99	$51.95	$14.95 ▼ $52.00	$3.71B	1.22	1.68 million shs	113 shs
INSM Insmed	$102.56 -1.5%	$86.93	$60.40 ▼ $106.83	$19.76B	0.9	2.30 million shs	1.43 million shs
PTCT PTC Therapeutics	$47.63 -1.9%	$48.83	$29.02 ▼ $58.38	$3.85B	0.5	875,491 shs	628,561 shs
SAGE Sage Therapeutics	$9.11 -0.3%	$7.93	$4.62 ▼ $13.47	$572.35M	0.29	1.34 million shs	1.94 million shs
SDGR Schrodinger	$21.45 -0.9%	$21.99	$16.60 ▼ $28.47	$1.59B	1.58	926,705 shs	962,275 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CCXI ChemoCentryx	0.00%	0.00%	0.00%	0.00%	0.00%
INSM Insmed	-0.40%	+7.77%	+3.88%	+43.63%	+37.90%
PTCT PTC Therapeutics	+0.81%	-2.00%	-4.56%	+2.41%	+41.94%
SAGE Sage Therapeutics	+0.11%	-0.76%	+0.22%	+23.01%	-24.77%
SDGR Schrodinger	+1.88%	-0.28%	+3.69%	-15.92%	-6.56%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CCXI ChemoCentryx	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
INSM Insmed	3.8659 of 5 stars	2.5	4.0	0.0	4.3	2.2	1.7	0.6
PTCT PTC Therapeutics	4.4456 of 5 stars	4.3	1.0	0.0	4.4	2.8	0.8	1.3
SAGE Sage Therapeutics	3.3638 of 5 stars	2.0	4.0	0.0	4.1	1.4	1.7	0.6
SDGR Schrodinger	1.8305 of 5 stars	3.4	1.0	0.0	0.0	1.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CCXI ChemoCentryx	0.00	N/A	N/A	N/A
INSM Insmed	3.00	Buy	$108.47	5.76% Upside
PTCT PTC Therapeutics	2.67	Moderate Buy	$65.00	36.47% Upside
SAGE Sage Therapeutics	1.94	Reduce	$8.75	-3.99% Downside
SDGR Schrodinger	2.75	Moderate Buy	$32.75	52.68% Upside

Current Analyst Ratings Breakdown

Latest CCXI, SDGR, SAGE, PTCT, and INSM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2025	INSM Insmed	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$102.00 ➝ $108.00
7/14/2025	SDGR Schrodinger	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$32.00 ➝ $30.00
7/8/2025	INSM Insmed	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$90.00 ➝ $111.00
7/8/2025	SAGE Sage Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$12.00 ➝ $9.20
7/3/2025	SDGR Schrodinger	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$28.00
6/20/2025	SAGE Sage Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$7.00 ➝ $9.00
6/17/2025	PTCT PTC Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$80.00
6/17/2025	SAGE Sage Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$9.00 ➝ $8.50
6/17/2025	SAGE Sage Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Hold ➝ Hold	$8.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$12.00
6/17/2025	SAGE Sage Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$8.00 ➝ $8.50

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CCXI ChemoCentryx	$32.22M	115.14	N/A	N/A	$4.09 per share	12.71
INSM Insmed	$363.71M	53.49	N/A	N/A	$1.60 per share	64.10
PTCT PTC Therapeutics	$806.78M	4.68	N/A	N/A	($14.24) per share	-3.34
SAGE Sage Therapeutics	$41.24M	13.83	N/A	N/A	$7.60 per share	1.20
SDGR Schrodinger	$207.54M	7.58	N/A	N/A	$5.78 per share	3.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CCXI ChemoCentryx	-$131.76M	-$1.89	N/A	N/A	N/A	-357.01%	-48.52%	-30.59%	N/A
INSM Insmed	-$913.77M	-$5.95	N/A	N/A	N/A	-265.93%	-446.98%	-52.70%	8/6/2025 (Estimated)
PTCT PTC Therapeutics	-$363.30M	$6.51	6.69	N/A	N/A	33.56%	-78.56%	32.11%	8/6/2025 (Estimated)
SAGE Sage Therapeutics	-$400.67M	-$5.80	0.00	N/A	N/A	-747.63%	-68.99%	-60.67%	7/30/2025 (Estimated)
SDGR Schrodinger	-$187.12M	-$2.63	0.00	N/A	N/A	-83.39%	-44.74%	-26.29%	7/30/2025 (Estimated)

Latest CCXI, SDGR, SAGE, PTCT, and INSM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	INSM Insmed	-$1.31	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	PTCT PTC Therapeutics	-$1.07	N/A	N/A	N/A	N/A	N/A
7/30/2025	Q2 2025	SAGE Sage Therapeutics	-$0.96	N/A	N/A	N/A	$16.69 million	N/A
7/30/2025	Q2 2025	SDGR Schrodinger	-$0.83	N/A	N/A	N/A	$52.03 million	N/A
5/8/2025	Q1 2025	INSM Insmed	-$1.36	-$1.42	-$0.06	-$1.42	$91.63 million	$92.82 million
5/7/2025	Q1 2025	SDGR Schrodinger	-$0.81	-$0.82	-$0.01	-$0.82	$54.60 million	$59.55 million
5/6/2025	Q1 2025	PTCT PTC Therapeutics	$0.85	$10.04	+$9.19	N/A	$437.16 million	$1.18 billion
4/29/2025	Q1 2025	SAGE Sage Therapeutics	-$0.99	-$1.01	-$0.02	-$1.01	$14.12 million	$14.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CCXI ChemoCentryx	N/A	N/A	N/A	N/A	N/A
INSM Insmed	N/A	N/A	N/A	N/A	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A
SAGE Sage Therapeutics	N/A	N/A	N/A	N/A	N/A
SDGR Schrodinger	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CCXI ChemoCentryx	0.02	4.54	4.47
INSM Insmed	11.38	5.86	5.44
PTCT PTC Therapeutics	N/A	3.89	3.85
SAGE Sage Therapeutics	N/A	9.13	9.13
SDGR Schrodinger	N/A	3.45	3.45

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CCXI ChemoCentryx	81.09%
INSM Insmed	N/A
PTCT PTC Therapeutics	N/A
SAGE Sage Therapeutics	99.22%
SDGR Schrodinger	79.05%

Insider Ownership

Company	Insider Ownership
CCXI ChemoCentryx	8.30%
INSM Insmed	3.00%
PTCT PTC Therapeutics	5.50%
SAGE Sage Therapeutics	5.50%
SDGR Schrodinger	8.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CCXI ChemoCentryx	178	71.36 million	65.43 million	Optionable
INSM Insmed	1,271	189.71 million	184.02 million	Optionable
PTCT PTC Therapeutics	1,410	79.26 million	74.90 million	Optionable
SAGE Sage Therapeutics	690	62.62 million	59.18 million	Optionable
SDGR Schrodinger	790	73.38 million	67.07 million	Optionable

CCXI, SDGR, SAGE, PTCT, and INSM Headlines

Recent News About These Companies

Material Informatics Company Evaluation Report 2025 | Schrodinger, Dassault Systèmes, and Citrine Informatics Drive Market Growth Through AI, Simulation, and Collaboration

July 18 at 10:25 AM | globenewswire.com

Massachusetts Financial Services Co. MA Sells 186,228 Shares of Schrodinger, Inc. (NASDAQ:SDGR)

July 18 at 5:38 AM | marketbeat.com

Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target

July 17 at 10:30 AM | finance.yahoo.com

Schrodinger (NASDAQ:SDGR) Given New $30.00 Price Target at KeyCorp

July 15 at 4:44 AM | americanbankingnews.com

KeyCorp Has Lowered Expectations for Schrodinger (NASDAQ:SDGR) Stock Price

July 14, 2025 | marketbeat.com

Schrodinger, Inc. (NASDAQ:SDGR) Position Raised by Stephens Investment Management Group LLC

July 13, 2025 | marketbeat.com

BMO Capital Remains a Buy on Schrodinger (SDGR)

July 11, 2025 | theglobeandmail.com

Morgan Stanley Assumes Coverage on Schrödinger (SDGR) Stock

July 10, 2025 | finance.yahoo.com

Allspring Global Investments Holdings LLC Boosts Holdings in Schrodinger, Inc. (NASDAQ:SDGR)

July 7, 2025 | marketbeat.com

SDGR - Schrodinger Inc Ordinary Shares Financials - Morningstar

July 5, 2025 | morningstar.comM

MS initiates coverage on AI Biotechs, flags key pipeline catalysts

July 3, 2025 | investing.com

Schrödinger (SDGR) Receives FDA Fast Track Designation for Cancer Drug SGR-1505

July 3, 2025 | msn.com

Morgan Stanley Initiates Coverage on Schrodinger (NASDAQ:SDGR)

July 3, 2025 | marketbeat.com

Schrödinger, Inc. (SDGR) - Yahoo Finance

July 2, 2025 | finance.yahoo.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR

July 2, 2025 | prnewswire.com

Short SDGR: Schrödinger bounces from 2024 midpoint, trading range low as potential short-term target

July 1, 2025 | invezz.comI

Sumitomo Mitsui Trust Group Inc. Sells 48,103 Shares of Schrodinger, Inc. (NASDAQ:SDGR)

July 1, 2025 | marketbeat.com

Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia

June 27, 2025 | tmcnet.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR

June 23, 2025 | globenewswire.com

17,493 Shares in Schrodinger, Inc. (NASDAQ:SDGR) Bought by Palumbo Wealth Management LLC

June 23, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR

June 22, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CCXI, SDGR, SAGE, PTCT, and INSM Company Descriptions

ChemoCentryx NASDAQ:CCXI

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.

Insmed NASDAQ:INSM

$102.56 -1.61 (-1.55%)

Closing price 04:00 PM Eastern

Extended Trading

$102.74 +0.17 (+0.17%)

As of 06:15 PM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

PTC Therapeutics NASDAQ:PTCT

$47.63 -0.90 (-1.85%)

Closing price 04:00 PM Eastern

Extended Trading

$47.62 -0.01 (-0.02%)

As of 04:33 PM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Sage Therapeutics NASDAQ:SAGE

$9.11 -0.03 (-0.33%)

Closing price 04:00 PM Eastern

Extended Trading

$9.11 0.00 (0.00%)

As of 04:42 PM Eastern

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Schrodinger NASDAQ:SDGR

$21.45 -0.20 (-0.92%)

Closing price 04:00 PM Eastern

Extended Trading

$21.74 +0.29 (+1.33%)

As of 07:57 PM Eastern

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time